Pune (1st April 2020)

geneOmbio Technologies is a leading biotechnology research organization in India. Company offer molecular research and diagnostics services. A group of researchers at geneOmbio have developed an optimized technology to isolate RNA from swab samples and enhance the chances of identifying COVID-19 positive cases, due to its modified workflow. The “geneOmbio Viral Nucleic Acid Extraction” kit version 2.0 uses spin column-based technology to purify the ribonucleic acid (RNA) from the patient’s swab. Except a few domestic players involved in RNA extraction kit manufacturing, the majority of RNA isolation kits are imported and its non-availability often becomes a severe bottleneck for RT-PCR (Reverse transcriptase- Polymerase chain reaction) testing in large numbers across the country

The kit can be further deployed for both DNA and RNA virus infected clinical samples. In current SARS-COV-2 pandemic, the causative virus, is a virus that uses RNA, a long single stranded polymeric substance present in all living cells and carries the genetic information of the organism necessary for life. One of the critical steps in detecting this virus is by confirming the presence of the RNA of the virus in the sample taken from the throat or nose. In the lab, the RNA of SARS-CoV-2 is extracted, converted into DNA and amplified using the PCR technique. The kit uses Proteinase K for efficient digestion of proteins and nucleases. Use of carrier RNA in this kit effectively enhances coprecipitation of viral RNA even if it is present if few copies thus enhancing the detection sensitivity.

The kit received ICMR-NIV approval as per the validation exercise conducted by ICMR-NIV, Pune, getting 100% concordant results in comparative analysis with standard methods.

The commercial supply of these kits from geneOmbio technologies Pvt. Ltd., Pune is set to begin from June 8th, 2020 to all private and Government laboratories performing COVID-19 diagnostic testing.